EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)

EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)

OSLO/LONDON, 22 December 2021: Christmas came early at EXACT Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX) as the clinical-stage precision health company developing the proprietary ultrasound-mediated drug delivery platform Acoustic Cluster Therapy (ACT®) for use across multiple diseases, announces today that allowability has been found for its patent application in Europe (publication no. EP3049117) for its innovative Acoustic Cluster Therapy® technology.

The allowed patent claims cover EXACT-Tx`s unique microbubble/ microdroplet formulation (PS101) and its use, co-administered with a range of pharmaceutical agents for ultrasound mediated drug targeting. This is an important step in securing EXACT-Tx’s mission to enhance the therapeutic outcome of the standard of care across drug classes for the benefit of patients across diseases.

Dr Masha Strømme, Executive Chair of the Board, commented: “We are delighted with the decision of the European Patent Office in allowing this important patent for ACT®, which complements the existing grant in China in November 2019 and in Japan in April 2021. This core patent family represents the foundation of our dynamic IP strategy, which encompasses the use of ACT® with a variety of therapeutics across a multitude of indications”.